Kei Miyakawa

2.1k total citations
68 papers, 1.3k citations indexed

About

Kei Miyakawa is a scholar working on Infectious Diseases, Molecular Biology and Epidemiology. According to data from OpenAlex, Kei Miyakawa has authored 68 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Infectious Diseases, 17 papers in Molecular Biology and 17 papers in Epidemiology. Recurrent topics in Kei Miyakawa's work include SARS-CoV-2 and COVID-19 Research (20 papers), HIV Research and Treatment (15 papers) and SARS-CoV-2 detection and testing (11 papers). Kei Miyakawa is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (20 papers), HIV Research and Treatment (15 papers) and SARS-CoV-2 detection and testing (11 papers). Kei Miyakawa collaborates with scholars based in Japan, United States and Singapore. Kei Miyakawa's co-authors include Akihide Ryo, Yutaro Yamaoka, Sundararaj Stanleyraj Jeremiah, Takeshi Morita, Takaji Wakita, Satoko Matsunaga, Naoki Yamamoto, Hirokazu Kimura, Mayuko Nishi and Koichi Watashi and has published in prestigious journals such as Nature Communications, SHILAP Revista de lepidopterología and Gastroenterology.

In The Last Decade

Kei Miyakawa

63 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kei Miyakawa Japan	18	394	379	271	199	198	68	1.3k
Farah Bokharaei‐Salim Iran	24	430 1.1×	734 1.9×	770 2.8×	198 1.0×	121 0.6×	106	2.2k
Seyed Hamidreza Monavari Iran	20	353 0.9×	209 0.6×	609 2.2×	84 0.4×	109 0.6×	98	1.5k
Ramin Sarrami‐Forooshani Iran	16	215 0.5×	335 0.9×	291 1.1×	274 1.4×	116 0.6×	45	991
María J. Gómara Spain	22	217 0.6×	554 1.5×	249 0.9×	192 1.0×	73 0.4×	81	1.3k
Fahad N. Almajhdi Saudi Arabia	19	289 0.7×	233 0.6×	414 1.5×	154 0.8×	202 1.0×	81	1.2k
Mohsen Moghoofei Iran	30	249 0.6×	1.2k 3.2×	548 2.0×	263 1.3×	232 1.2×	66	2.5k
Saman Yasamineh Iran	21	156 0.4×	483 1.3×	124 0.5×	80 0.4×	170 0.9×	42	1.2k
Darong Yang China	21	116 0.3×	475 1.3×	162 0.6×	311 1.6×	184 0.9×	36	1.1k
Veronica D. Gonzalez Argentina	19	131 0.3×	413 1.1×	200 0.7×	841 4.2×	87 0.4×	50	1.5k
Edward L.G. Pryzdial Canada	24	287 0.7×	349 0.9×	247 0.9×	472 2.4×	93 0.5×	60	1.9k

Countries citing papers authored by Kei Miyakawa

Since Specialization

Citations

This map shows the geographic impact of Kei Miyakawa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kei Miyakawa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kei Miyakawa more than expected).

Fields of papers citing papers by Kei Miyakawa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kei Miyakawa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kei Miyakawa. The network helps show where Kei Miyakawa may publish in the future.

Co-authorship network of co-authors of Kei Miyakawa

This figure shows the co-authorship network connecting the top 25 collaborators of Kei Miyakawa. A scholar is included among the top collaborators of Kei Miyakawa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kei Miyakawa. Kei Miyakawa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sano, Kaori, Kei Miyakawa, Hideaki Kato, et al.. (2025). Neutralizing antibody evasion of SARS-CoV-2 JN.1 derivatives KP.3, KP.3.1.1, LB.1, and XEC. Vaccine. 62. 127472–127472. 1 indexed citations

Koma, Takaaki, Kei Miyakawa, Taiki Morita, et al.. (2025). Positive correlation between structural disorder of the HIV-1 Gag N-terminal segment and progeny virus particle formation. Journal of Virology. 99(10). e0088725–e0088725.

Sano, Kaori, Yayoi Kimura, Atsushi Goto, et al.. (2024). Cellular and humoral immunity and IgG subclass distribution after omicron XBB.1.5 monovalent vaccination in Japan. Vaccine. 42(26). 126452–126452. 1 indexed citations

Okura, Takashi, Kei Miyakawa, Maino Tahara, et al.. (2024). Rapid quantitative detection system for measles virus‐neutralizing antibodies using HiBiT‐tagged virus‐like particles. Microbiology and Immunology. 68(4). 160–164.

Ino, Yoko, Yutaro Yamaoka, Kei Miyakawa, et al.. (2023). Integrated tandem affinity protein purification using the polyhistidine plus extra 4 amino acids (HiP4) tag system. PROTEOMICS. 23(11). e2200334–e2200334. 4 indexed citations

Nishi, Mayuko, Kensuke Tateishi, Sundararaj Stanleyraj Jeremiah, et al.. (2023). Development of a contacting transwell co-culture system for the in vitro propagation of primary central nervous system lymphoma. Frontiers in Cell and Developmental Biology. 11. 1275519–1275519. 1 indexed citations

Goto, Atsushi, Kei Miyakawa, Izumi Nakayama, et al.. (2023). Prediction models for neutralization activity against emerging SARS-CoV-2 variants: A cross-sectional study. Frontiers in Microbiology. 14. 4 indexed citations

Yamaoka, Yutaro, Sundararaj Stanleyraj Jeremiah, Kei Miyakawa, et al.. (2022). Characterization and Utilization of Disulfide-Bonded SARS-CoV-2 Receptor Binding Domain of Spike Protein Synthesized by Wheat Germ Cell-Free Production System. Viruses. 14(7). 1461–1461. 6 indexed citations

Mitsunaga, Makoto, Kimihiro Ito, Takashi Nishimura, et al.. (2022). Antimicrobial strategy for targeted elimination of different microbes, including bacterial, fungal and viral pathogens. Communications Biology. 5(1). 647–647. 15 indexed citations

10.

Murai, Kazuhiro, Takahiro Kodama, Hayato Hikita, et al.. (2022). Inhibition of nonhomologous end joining‐mediated DNA repair enhances anti‐HBV CRISPR therapy. Hepatology Communications. 6(9). 2474–2487. 9 indexed citations

11.

Ino, Yoko, Mayuko Nishi, Yutaro Yamaoka, et al.. (2022). Phosphopeptide enrichment using Phos-tag technology reveals functional phosphorylation of the nucleocapsid protein of SARS-CoV-2. Journal of Proteomics. 255. 104501–104501. 13 indexed citations

12.

Nagata, Kayoko, Daichi Utsumi, Ryota Maeda, et al.. (2022). Intratracheal trimerized nanobody cocktail administration suppresses weight loss and prolongs survival of SARS-CoV-2 infected mice. SHILAP Revista de lepidopterología. 2(1). 152–152. 5 indexed citations

13.

Sekiba, Kazuma, Motoyuki Otsuka, Eri Tanaka, et al.. (2021). HBx-induced degradation of Smc5/6 complex impairs homologous recombination-mediated repair of damaged DNA. Journal of Hepatology. 76(1). 53–62. 60 indexed citations

14.

Hikita, Hayato, Kazuhiro Murai, Tasuku Nakabori, et al.. (2021). Capsid Allosteric Modulators Enhance the Innate Immune Response in Hepatitis B Virus–Infected Hepatocytes During Interferon Administration. Hepatology Communications. 6(2). 281–296. 4 indexed citations

15.

Miyakawa, Kei, Sundararaj Stanleyraj Jeremiah, Yutaro Yamaoka, et al.. (2021). Persistence of Robust Humoral Immune Response in Coronavirus Disease 2019 Convalescent Individuals Over 12 Months After Infection. Open Forum Infectious Diseases. 9(2). ofab626–ofab626. 5 indexed citations

16.

Kato, Hideaki, Kei Miyakawa, Yutaro Yamaoka, et al.. (2021). Antibody titers against the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 induced by BNT162b2 vaccination measured using automated chemiluminescent enzyme immunoassay. Journal of Infection and Chemotherapy. 28(2). 273–278. 16 indexed citations

17.

Murai, Kazuhiro, Hayato Hikita, Yugo Kai, et al.. (2020). Hepatitis C virus infection suppresses hepatitis B virus replication via the RIG-I-like helicase pathway. Scientific Reports. 10(1). 941–941. 17 indexed citations

18.

Matsunaga, Satoko, Sundararaj Stanleyraj Jeremiah, Kei Miyakawa, et al.. (2020). Engineering Cellular Biosensors with Customizable Antiviral Responses Targeting Hepatitis B Virus. iScience. 23(3). 100867–100867. 11 indexed citations

19.

Nie, Yunzhong, Yun‐Wen Zheng, Kei Miyakawa, et al.. (2018). Recapitulation of hepatitis B virus–host interactions in liver organoids from human induced pluripotent stem cells. EBioMedicine. 35. 114–123. 146 indexed citations

20.

Miyakawa, Kei, et al.. (2008). Effects of the ligand sequence modifications on the retargeted transduction by the retroviral vector having a ligand-chimeric Env protein. Journal of General Virology. 89(12). 3137–3143. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact